EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 5, 2003, Pages 1801-1806

  Clarijs, Ruud ^a   Schalkwijk, Lia ^b   Ruiter, Dirk J ^b   De Waal, Robert M W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADOLESCENT; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CELL INFILTRATION; CELLULAR DISTRIBUTION; CHEMOTAXIS; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UVEA MELANOMA; VASCULAR ENDOTHELIUM;

APOPTOSIS; CELL COUNT; CELL MOVEMENT; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MELANOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RNA-BINDING PROTEINS; UVEAL NEOPLASMS; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 0037406874     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0624     Document Type: Article

References (45)

1. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma. Hum Phatol. 1992;23:1298-1305.
2. Folberg R, Rummelt V, Parys-van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
3. Warso MA, Maniotis AJ, Chen X, et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 2001;7:473-477.
4. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 2000;91:359-367.
5. Clarijs R, Otte-Höller I, Ruiter DJ, de Waal RM. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43:912-918.
6. Mäkitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (cd68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-1421.
7. Mäkitie T, Tarkkanen A, Kivela T. Comparative immunohistochemical oestrogen receptor analysis in primary and metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1998;236:415-419.
8. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
9. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625-4629.
10. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57:138-142.
11. Vacca A, Ribatti D, Ruco L, Giacchetta F, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer. 1999;79:965-970.
12. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol. 2001;159:893-903.
13. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1422-1428.
14. Kao J, Houck K, Fan Y, et al. Characterization of a novel tumorderived cytokine: endothelial-monocyte activating polypeptide II. J Biol Chem. 1994;269:25106-25119.
15. Kao J, Ryan J, Brett G, et al. Endothelial monocyte-activating polypeptide II: a novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem. 1992;267:20239-20247.
16. Schwarz M, Lee M, Zhang F, et al. EMAP II: a modulator of neovascularization in the developing lung. Am J Physiol. 1999;276:L365-L375.
17. Knies UE, Behrensdorf HA, Mitchell CA, et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci USA. 1998;95:12322-12327.
18. Schwarz MA, Kandel J, Brett J, et al. Endothelial-monocyte activating polypeptide II: a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med. 1999;190:341-354.
19. Marvin MR, Libutti SK, Kayton M, et al. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res. 1996;63:248-255.
20. Barnett G, Jakobsen AM, Tas M, et al. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res. 2000;60:2850-2857.
21. Fauser S, Nguyen TD, Bekure K, Schluesener HJ, Meyermann R. Differential activation of microglial cells in local and remote areas of IRBP1169-1191-induced rat uveitis. Acta Neuropathol (Berl). 2001;101:565-571.
22. Zhang F, Schwarz MA. Temporo-spatial distribution of endothelialmonocyte activating polypeptide II: an anti-angiogenic protein, in the mouse embryo. Dev Dyn. 2000;218:490-498.
23. Knies UE, Kroger S, Clauss M. Expression of EMAP II in the developing and adult mouse. Apoptosis. 2000;5:141-151.
24. Schluesener HJ, Seid K, Deininger M, Schwab J. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides. J Neuroimmunol. 2001;113:89-94.
25. Schluesener HJ, Seid K, Zhao Y, Meyermann R. Localization of endothelial-monocyte-activating polypeptide II (EMAP II), a novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: expression by monocytes and activated microglial cells. Glia. 1997;20:365-372.
26. Tas MPR, Murray C. Endothelial-monocyte-activating polypeptide II. Int J Biochem Cell Biol. 1996;28:837-841.
27. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767-804.
28. Chang SY, Park SG, Kim S, Kang CY. Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase: its functional implication in endothelial cell proliferation. J Biol Chem. 2002;277:8388-8394.
29. Wu PC, Alexander HR, Huang J, et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res. 1999;59:205-212.
30. Gnant MF, Berger AC, Huang J, et al. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res. 1999;59:4668-4674.
31. Ortega N, Jonca F, Vincent S, et al. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am J Pathol. 1997;151:1215-1224.
32. Rose M, Page C, Hengstenberg C, Yacoub M. Immunocytochemical markers of activation in cardiac transplant rejection. Eur Heart J 1991;12(suppl D):147-150.
33. Foss AJ, Alexander RA, Hungerford JL, et al. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol. 1997;81:240-246.
34. Daemen MARC, van't Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999;104:541-549.
35. Verbeek MM, Otte-Holler I, Westphal JR, et al. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol. 1994;144:104-116.
36. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem. 1995;43:347-352.
37. Mäkitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-2480.
38. Facchetti F, Bertalot G, Grigolato PG. KP1 (CD 68) staining of malignant melanomas. Histopathology. 1991;19:141-145.
39. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739-752.
40. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-540.
41. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001;61:6322-6327.
42. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90:4304-4308.
43. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest. 1984;51:635-642.
44. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55:410-422.
45. Kao J, Fan YG, Haehnel I, et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem. 1994;269:9774-9782.